References
1. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., et al.; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113 (14): 1807-16.
2. Roberts A.M., Ware J.S., Herman D.S., Schafer S., et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015; 7 (270): 270ra6. doi: 10.1126/scitranslmed.3010134.
3. Akinrinade O., Koskenvuo J.W., Alastalo T.-P. Prevalence of titin truncating variants in general population. PLoS One. 2015; 10 (12): e0145284. doi: 10.1371/journal.pone.0145284.
4. Rusconi P., Wilkinson J.D., Sleeper L.A., Lu M., et al.; for the Pediatric Cardiomyopathy Registry Investigators. Differences in Presentation and Outcomes between Children with Familial Dilated Cardiomyopathy and Children with Idiopathic Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry Study Group. Circ Heart Fail. 2017; 10: e002637. doi: 10.1161/CIRCHEARTFAILURE.115.002637.
5. Bollen I.A.E., van der Meulen M., de Goede K., Kuster D.W.D., et al. Cardiomyocyte hypocontractility and reduced myofibril density in end-stage pediatric cardiomyopathy. Front Physiol. 2017; 8: 1103. doi: 10.3389/fphys.2017.01103. eCollection 2017.
6. Everitt M.D., Sleeper L.A., Lu M., Canter C.E., et al.; Pediatric Cardiomyopathy Registry Investigators. Recovery of echocar- diographic function in children with idiopathic dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. J Am Coll Cardiol. 2014; 63 (14): 1405-13.
7. Ackerman M.J., Priori S.G., Willems S., Berul C., et al.; Heart Rhythm Society (HRS); European Heart Rhythm Association (EHRA).HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011; 13 (8): 1077-109.
8. Dellefave L., McNally E.M. The genetics of dilated cardiomyopathy. Curr Opin Cardiol. 2010; 25 (3): 198-204.
9. Herman D.S., Lam L., Taylor M.R., Wang L., et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012; 366 (7): 619-28. PubMed Central PMCID: PMC3660031.
10. Gigli M., Begay R.L., Morea G., Graw S.L., et al. A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies. Front Cardiovasc Med. 2016; 3: 21.
11. Verdonschot J.A.J., Hazebroek M.R., Derks K.W.J., Barandiar n Aizpurua A., et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J. 2018 Jan 25.
12. Franaszczyk M., Chmielewski P., Truszkowska G., Stawinski P., et al. Titin truncating variants in dilated cardiomyopathy - prevalence and genotype-phenotype correlations. PLoS One. 2017; 12 (1): e0169007.
13. Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun. 2002; 291: 385-93.
14. Tobita T., Nomura S., Fujita T., Morita H., et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep. 2018; 8 (1): 1998. doi: 10.1038/s41598-018-20114-9.
15. Haas J., Frese K.S., Peil B., Kloos W., et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015; 36 (18): 1123-35.
16. Tayal U., Newsome S., Buchan R., et al. Phenotype and clinical outcomes of titin cardiomyopathy. J Am Coll Cardiol. 2017; 70 (18): 2264-74. doi: 10.1016/j.jacc.2017.08.063.
17. Akinrinade O., Alastalo T.P., Koskenvuo J.W. Relevance of truncating titin mutations in dilated cardiomyopathy. Clin Genet. 2016; 90 (1): 49-54. doi: 10.1111/cge.12741.
18. URL: http://www.umd.be/HSF3/
19. URL: http://www.cbs.dtu.dk/services/NetGene2/
20. Roberts A.M., Ware J.S., Herman D.S., Schafer S., et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015; 7 (270): 270ra6. PubMed Central PMID: PMC4560092.Gerull B., Atherton J., Geupel A., Sasse-Klaassen S., et al. Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. J Mol Med. 2006; 84: 478-83.
21. Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., et al. Functional analysis of titin/connectin N2-B mutations found in cardiomyopathy. J Muscle Res Cell Motil. 2005; 26: 367-74.
22. Tayal U., Newsome S., Buchan R., Whiffin N., et al. Phenotype and clinical outcomes of titin cardiomyopathy. J Am Coll Cardiol. 2017; 70 (18): 2264-74. doi: 10.1016/j.jacc.2017.08.063.
23. Tayal U., Newsome S., Buchan R., Whiffin N., et al. Truncating variants in titin independently predict early arrhythmias in patients with dilated cardiomyopathy. J Am Coll Cardiol Lett. 2017; 69 (19): 2466-8.
24. Taylor M., Graw S., Sinagra G., Barnes C., et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy - overlap syndromes. Circulation. 2011; 124 (8): 876-85. PMID: 21810661.